Evidence map›Paper›PMID 38733195›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2024

[Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy].

J Zhao, X Y Chen, S J Zheng

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J ZhaoFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
X Y ChenFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
S J ZhengFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Funding

Beijing Natural Science Foundation 7222093Capital Clinical Diagnostic Techniques and Translational Application Projects Z211100002921059High-Level Public Health Technical Talents Construction Project of Beijing Municipal Health Commission Academic Leader -02-14
6 · The paper itself

Abstract

Hepatitis B virus (HBV) DNA integration occurs during the reverse transcription process of HBV replication, which develops in the early stages of HBV infection and accompanies the entire disease course. The integration of HBV DNA is detrimental to the attainment of clinical cure goals and also raises the risk of developing liver cancer. Theoretically, nucleos(t)ide analogs can reduce the synthesis of new double-stranded linear DNA, but there is no clearance function for hepatocytes that have already integrated HBV. Therefore, patients with serum HBV DNA-negative conversions still have the risk of developing liver cancer. As an immunomodulatory drug, interferon can not only inhibit viral replication but also inhibit or even eliminate existing clonally amplified hepatocytes carrying integrated HBV DNA fragments. However, there are currently few studies on the effects of nucleos(t)ide analogues and interferon therapy on HBV DNA integration. Thus, large-scale clinical studies are urgently needed for further clarification.

Indexed as

Antiviral AgentsHepatitis BHepatitis B virusDNA, ViralHumansInterferonsVirus IntegrationVirus ReplicationAntiviral AgentsDNA, ViralInterferonsClinical cureDNA integrationHepatitis B virusHepatocellular carcinomaInterferonNucleos(t)ide-analogues

Identifiers

PMID38733195
PMCPMC12822499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.